Efficacy and safety of CHF6001, a novel inhaled PDE4 inhibitor in COPD: the PIONEER study

[1]  H. Watz,et al.  Sputum and blood transcriptomics characterisation of the inhaled PDE4 inhibitor CHF6001 on top of triple therapy in patients with chronic bronchitis , 2020, Respiratory Research.

[2]  H. Watz,et al.  Effect of the inhaled PDE4 inhibitor CHF6001 on biomarkers of inflammation in COPD , 2019, Respiratory Research.

[3]  F. Martinez,et al.  Determinants of Response to Roflumilast in Severe Chronic Obstructive Pulmonary Disease. Pooled Analysis of Two Randomized Trials , 2018, American journal of respiratory and critical care medicine.

[4]  H. Watz,et al.  Anti-inflammatory effects of roflumilast in chronic obstructive pulmonary disease (ROBERT): a 16-week, randomised, placebo-controlled trial. , 2018, The Lancet. Respiratory medicine.

[5]  A. Pottegård,et al.  Roflumilast Usage from 2010 to 2016: A Danish Nationwide Drug Utilization Study , 2018, Basic & clinical pharmacology & toxicology.

[6]  D. Tashkin,et al.  Effect of budesonide/formoterol pressurized metered-dose inhaler on exacerbations versus formoterol in chronic obstructive pulmonary disease: The 6-month, randomized RISE (Revealing the Impact of Symbicort in reducing Exacerbations in COPD) study. , 2017, Respiratory medicine.

[7]  R. Golpe,et al.  Intolerance to roflumilast in real-life clinical practice. , 2017, European journal of internal medicine.

[8]  K. Rabe,et al.  Effect of Roflumilast and Inhaled Corticosteroid/Long-Acting β2-Agonist on Chronic Obstructive Pulmonary Disease Exacerbations (RE(2)SPOND). A Randomized Clinical Trial. , 2016, American journal of respiratory and critical care medicine.

[9]  E. Hirsch,et al.  CHF6001 I: A Novel Highly Potent and Selective Phosphodiesterase 4 Inhibitor with Robust Anti-Inflammatory Activity and Suitable for Topical Pulmonary Administration , 2015, The Journal of Pharmacology and Experimental Therapeutics.

[10]  A. Sala,et al.  CHF6001 II: A Novel Phosphodiesterase 4 Inhibitor, Suitable for Topical Pulmonary Administration—In Vivo Preclinical Pharmacology Profile Defines a Potent Anti-Inflammatory Compound with a Wide Therapeutic Window , 2015, The Journal of Pharmacology and Experimental Therapeutics.

[11]  C. Montón,et al.  Roflumilast added to triple therapy in patients with severe COPD: a real life study. , 2015, Pulmonary pharmacology & therapeutics.

[12]  F. Martinez,et al.  Reduction of exacerbations by the PDE4 inhibitor roflumilast - the importance of defining different subsets of patients with COPD , 2011, Respiratory research.

[13]  F. Martinez,et al.  Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials , 2009, The Lancet.

[14]  F. Martinez,et al.  Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials , 2009, The Lancet.

[15]  J A Anderson,et al.  Adherence to inhaled therapy, mortality and hospital admission in COPD , 2009, Thorax.

[16]  S. Rennard,et al.  Efficacy and Tolerability of Budesonide/Formoterol in One Hydrofluoroalkane Pressurized Metered-Dose Inhaler in Patients with Chronic Obstructive Pulmonary Disease , 2009, Drugs.

[17]  S. Rennard,et al.  Efficacy and Safety of Budesonide and Formoterol in One Pressurized Metered-Dose Inhaler in Patients with Moderate to Very Severe Chronic Obstructive Pulmonary Disease , 2008, Drugs.

[18]  D. Sin,et al.  The effects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary disease. , 2008, American journal of respiratory and critical care medicine.

[19]  D. Sin,et al.  Circulating surfactant protein D as a potential lung-specific biomarker of health outcomes in COPD: a pilot study , 2007, BMC pulmonary medicine.

[20]  L. Fabbri,et al.  Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. , 2007, American journal of respiratory and critical care medicine.

[21]  E. Bateman,et al.  Roflumilast—an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial , 2005, The Lancet.

[22]  P. Calverley,et al.  Maintenance therapy with budesonide and formoterol in chronicobstructive pulmonary disease , 2003, European Respiratory Journal.

[23]  I. Pavord,et al.  Antiinflammatory effects of the phosphodiesterase-4 inhibitor cilomilast (Ariflo) in chronic obstructive pulmonary disease. , 2003, American journal of respiratory and critical care medicine.

[24]  W D Plummer,et al.  Power and sample size calculations for studies involving linear regression. , 1998, Controlled clinical trials.

[25]  A. Persson,et al.  Surfactant protein D: subcellular localization in nonciliated bronchiolar epithelial cells. , 1992, The American journal of physiology.

[26]  C. Lenfant,et al.  Global Initiative for chronic obstructive lung disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease , 2006 .

[27]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..